SecBot SecBot

Drug-price Transparency for Consumers Act of 2023

S. 1250 Sen. Richard Durbin (D-IL) In committee
Bill text PDF
  1. Introduced Apr 20
  2. Committee Apr 20
  3. Passed Senate Next
  4. Passed House Not yet
  5. To President Not yet
  6. Law Not yet
Where it stands
In committee, Apr 20, 2023Next: Senate vote
1287d ago Apr 20, 2023: Read twice and referred to the Committee on Finance. (Sponsor introductory remarks on measure: CR S1297; text: CR S1297-1298)
Final votes
No roll callsNo recorded vote on this bill yet
Lobbying
2companies, 2 filings
Subscribe to see spend
Member trades
5trades in the last 90 days
Subscribe to see who
Who backs the bill and who pushes back Subscribe

Companies lobbying on this bill

2 companies
Companies by sector
Biotech & Pharma 1Financials 1
Search all 2 companies, their asks and price moves Subscribe

Summary

Drug-price Transparency for Consumers Act of 2023 or the DTC Act of 2023 This bill requires consumer advertisements for drugs and biologicals to include certain price information if the drug or biological is (1) covered under Medicare or Medicaid, and (2) required to include a risk summary under current law. The requirement does not apply to advertisements for drugs or biologicals with a wholesale cost of less than $35 for a one-month supply. Each violation of this requirement is subject to a civil penalty of not more than $100,000.

Library of Congress summary, Apr 20, 2023

Summary versions
  • Introduced in SenateApr 20, 2023

Official record from Congress.gov, the House Clerk and the Senate; lobbying from Lobbying Disclosure Act filings. Updated Oct 28, 2026.